Darifenacin
- $39 - $2245.7
- Product name: Darifenacin
- CAS: 133099-04-4
- MF: C28H30N2O2
- MW: 426.55
- EINECS:
- MDL Number:MFCD00896313
- Synonyms:2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetaMide;UK 88525;UK88525;UK-88525;2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-dip;Darifenacin, >=98%;DARIFENACIN;2-[1-[2-(2,3-Dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-di(phenyl)acetamide
18 prices
Selected condition:
Brand
- AK Scientific
- American Custom Chemicals Corporation
- AvaChem
- Biorbyt Ltd
- Chemenu
- ChemScene
- Crysdot
- DC Chemicals
- Matrix Scientific
- Medical Isotopes, Inc.
Package
- 1mg
- 5mg
- 10MG
- 100MG
- 250mg
- 1g
- ManufacturerAK Scientific
- Product numberQ569
- Product descriptionDarifenacin
- Packaging250mg
- Price$815
- Updated2021-12-16
- Buy
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberAPI0002219
- Product descriptionDARIFENACIN 95.00%
- Packaging10MG
- Price$253.05
- Updated2021-12-16
- Buy
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberAPI0002219
- Product descriptionDARIFENACIN 95.00%
- Packaging100MG
- Price$1055.09
- Updated2021-12-16
- Buy
- ManufacturerAvaChem
- Product number2241B
- Product descriptionDarifenacin
- Packaging10mg
- Price$39
- Updated2021-12-16
- Buy
- ManufacturerAvaChem
- Product number2241B
- Product descriptionDarifenacin
- Packaging100mg
- Price$79
- Updated2021-12-16
- Buy
- ManufacturerAvaChem
- Product number2241B
- Product descriptionDarifenacin
- Packaging1g
- Price$179
- Updated2021-12-16
- Buy
- ManufacturerBiorbyt Ltd
- Product numberorb146146
- Product descriptionDarifenacin >98%
- Packaging100mg
- Price$578
- Updated2021-12-16
- Buy
- ManufacturerBiorbyt Ltd
- Product numberorb146146
- Product descriptionDarifenacin >98%
- Packaging250mg
- Price$1133.9
- Updated2021-12-16
- Buy
- ManufacturerBiorbyt Ltd
- Product numberorb146146
- Product descriptionDarifenacin >98%
- Packaging1g
- Price$2245.7
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM160502
- Product description2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-pyrrolidin-3-yl)-2,2-diphenylacetamide 98%
- Packaging100mg
- Price$436
- Updated2021-12-16
- Buy
- ManufacturerChemScene
- Product numberCS-1168
- Product descriptionDarifenacin
- Packaging5mg
- Price$80
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31003864
- Product descriptionDarifenacin 98+%
- Packaging10mg
- Price$64
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31003864
- Product descriptionDarifenacin 98+%
- Packaging100mg
- Price$466
- Updated2021-12-16
- Buy
- ManufacturerDC Chemicals
- Product numberDC3152
- Product descriptionDarifenacin >98%
- Packaging250mg
- Price$750
- Updated2021-12-16
- Buy
- ManufacturerDC Chemicals
- Product numberDC3152
- Product descriptionDarifenacin >98%
- Packaging1g
- Price$1500
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number093128
- Product description2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-pyrrolidin-3-yl)-2,2-diphenylacetamide 95+%
- Packaging250mg
- Price$567
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | Q569 | Darifenacin | 250mg | $815 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | API0002219 | DARIFENACIN 95.00% | 10MG | $253.05 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | API0002219 | DARIFENACIN 95.00% | 100MG | $1055.09 | 2021-12-16 | Buy |
AvaChem | 2241B | Darifenacin | 10mg | $39 | 2021-12-16 | Buy |
AvaChem | 2241B | Darifenacin | 100mg | $79 | 2021-12-16 | Buy |
AvaChem | 2241B | Darifenacin | 1g | $179 | 2021-12-16 | Buy |
Biorbyt Ltd | orb146146 | Darifenacin >98% | 100mg | $578 | 2021-12-16 | Buy |
Biorbyt Ltd | orb146146 | Darifenacin >98% | 250mg | $1133.9 | 2021-12-16 | Buy |
Biorbyt Ltd | orb146146 | Darifenacin >98% | 1g | $2245.7 | 2021-12-16 | Buy |
Chemenu | CM160502 | 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-pyrrolidin-3-yl)-2,2-diphenylacetamide 98% | 100mg | $436 | 2021-12-16 | Buy |
ChemScene | CS-1168 | Darifenacin | 5mg | $80 | 2021-12-16 | Buy |
Crysdot | CD31003864 | Darifenacin 98+% | 10mg | $64 | 2021-12-16 | Buy |
Crysdot | CD31003864 | Darifenacin 98+% | 100mg | $466 | 2021-12-16 | Buy |
DC Chemicals | DC3152 | Darifenacin >98% | 250mg | $750 | 2021-12-16 | Buy |
DC Chemicals | DC3152 | Darifenacin >98% | 1g | $1500 | 2021-12-16 | Buy |
Matrix Scientific | 093128 | 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-pyrrolidin-3-yl)-2,2-diphenylacetamide 95+% | 250mg | $567 | 2021-12-16 | Buy |
Properties
alpha :25D -20.6° (c = 1.0 in methylene chloride)
Boiling point :614.3±55.0 °C(Predicted)
Density :1.192±0.06 g/cm3(Predicted)
storage temp. :2-8°C
solubility :Soluble in DMSO
form :Powder
pka :pKa (25°): 9.2
color :White to off-white
Boiling point :614.3±55.0 °C(Predicted)
Density :1.192±0.06 g/cm3(Predicted)
storage temp. :2-8°C
solubility :Soluble in DMSO
form :Powder
pka :pKa (25°): 9.2
color :White to off-white
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|
Description
Darifenacin is a novel muscarinic M3 selective antagonist for the once-daily oral treatment of urinary incontinence and overactive bladder. The majority of overactive bladder symptoms are thought to result from the overactivity of the detrusor muscle, which is primarily mediated by acetylcholine-induced stimulation of muscarinic M3 receptors in the bladder. Consequently, antimuscarinic agents have become the mainstay of overactive bladder treatment. Darifenacin has a higher level of M3 selectivity than the previously marketed antimuscarinic agents. It has Ki values of 16nM for M1, 50 nM for M2, and 1.6 nM for M3 receptors. It is slightly more M3 selective than solifenacin (M1:Ki=25 nM, M2:Ki=126 nM, M3:Ki=10 nM), which was launched in 2004. Darifenacin is significantly more selective than other muscarinics such as tolterodine, oxybutynin, and trospium, which are all essentially equipotent against M1, M2, and M3 receptors. In addition,darifenacin demonstrates greater effect on tissues in which the predominant receptor type is M3 rather than M1 or M2. In vitro darifenacin inhibits carbacholinduced contractions with greater potency in isolated guinea-pig bladder (M3) than in guinea-pig atria (M2) or dog saphenous vein (M1). In animal models, it shows greater selectivity for inhibition of detrusor contraction over salivation or tachycardia.Darifenacin is supplied as a controlled release formulation, and the recommended dosage is 7.5 mg once, daily. Darifenacin is rapidly and completely absorbed from the GI tract after oral administration, with maximum plasma levels achieved after about 7 h. The elimination half-life is approximately 3 h, but because of the controlled release characteristics of the formulation, the drug is suitable for once-daily dosing. Steady-state plasma levels are achieved within 6 days of commencing treatment. Darifenacin exhibits high-protein binding (98%), a volume of distribution of 163 L, and a clearance of 40 L/h. It has low oral bioavailability (15–19%) due to extensive first-pass metabolism by CYP3A4 and CYP2D6, but this can be saturated after multiple administrations. The major circulating metabolites are produced by monohydroxylation and N-dealkylation; however, none contribute significantly to the overall clinical effect of darifenacin. Approximately 58% of the dose is excreted in urine and 44% in feces; only a small percentage (3%) of the excreted dose is unchanged darifenacin.More related product prices
Acetamide Piracetam Etanol 4-Acetamidophenol 2-Cyanoacetamide N,N-Dimethylacetamide Phenyl salicylate Thioacetamide Ethylparaben Ethyl acetate Trinexapac-ethyl Diphenyl oxide Phenylacetic acid Modafinil Darifenacin hydrobromide (S)-alpha,alpha-Diphenyl-3-pyrrolidineacetamide 127264-14-6 104706-47-0